KRAS and colorectal carcinoma: Molecular subtypes of CRC are associated with response to anti-EGFR therapies independent of KRAS mutations.44 In this study, we were able to demonstrate that the RNAMethyPro risk groups were significantly associated with various CRC subtypes and accordingly hypothesized that risk scores derived from this signature may also be predictive of therapeutic response to anti-EGFR drugs.